Annuncio pubblicitario
Italia markets close in 5 hours 36 minutes

  • FTSE MIB

    34.236,74
    +296,99 (+0,88%)
     

  • Dow Jones

    38.085,80
    -375,12 (-0,98%)
     

  • Nasdaq

    15.611,76
    -100,99 (-0,64%)
     

  • Nikkei 225

    37.934,76
    +306,28 (+0,81%)
     

  • Petrolio

    83,90
    +0,33 (+0,39%)
     

  • Bitcoin EUR

    59.988,11
    +493,86 (+0,83%)
     

  • CMC Crypto 200

    1.392,53
    -4,01 (-0,29%)
     

  • Oro

    2.360,40
    +17,90 (+0,76%)
     

  • EUR/USD

    1,0739
    +0,0006 (+0,05%)
     

  • S&P 500

    5.048,42
    -23,21 (-0,46%)
     

  • HANG SENG

    17.651,15
    +366,61 (+2,12%)
     

  • Euro Stoxx 50

    4.969,79
    +30,78 (+0,62%)
     

  • EUR/GBP

    0,8578
    +0,0004 (+0,05%)
     

  • EUR/CHF

    0,9787
    +0,0002 (+0,02%)
     

  • EUR/CAD

    1,4655
    +0,0006 (+0,04%)
     

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Inc.
·1 minuto per la lettura
Cingulate Inc.
Cingulate Inc.

KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST.

The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. Dr. Schaffer will also provide a company overview.

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

ANNUNCIO PUBBLICITARIO

About Cingulate® 
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.

Cingulate is headquartered in Kansas City. For more information visit Cingulate.com

Investor Relations 
Thomas Dalton 
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com 
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com 
214-597-8200

Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com 
201-723-5805